Literature DB >> 12059082

Comparison of quick and owren prothrombin time with regard to the harmonisation of the International Normalised Ratio (INR) system.

Juha Horsti1.   

Abstract

Prothrombin time (PT) is tested mostly to monitor patients on oral anticoagulant treatment. The International Normalised Ratio (INR) was introduced to improve and harmonise PT results and therapeutic range globally for patient care and the scientific literature. We studied the Quick PT in 179 patients and the Owren PT in 137 patients on oral anticoagulant therapy using two different reagents for the two methods of measuring PT. We assessed the clinical significance of the INR results obtained by each method using the two reagents and compared the Quick and Owren methods. We conclude that with the Quick method individual INR results differed from each other too much clinically, while using the Owren method individual INR results were clinically acceptable. Our opinion is that we should develop the INR system using the Owren PT method rather than the Quick to improve patient care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12059082     DOI: 10.1515/CCLM.2002.064

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  3 in total

1.  A New Generation Prothrombin Time Method for INR.

Authors:  Juha Horsti; Helena Uppa; Juhani A Vilpo
Journal:  Open Med Chem J       Date:  2008-02-27

2.  Evaluation of the Steelex M600H coagulometer prothrombin time-international normalized ratio assay with Steelex test reagents.

Authors:  Yasemin U Budak; Kağan Huysal; Murat Polat; Gülsevil Tarakçi; Hakan Uçar
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

Review 3.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.